Core Insights - Ascendis Pharma A/S shares have risen following the FDA's approval of Yuviwel, the first once-weekly treatment for children with achondroplasia [1] FDA Approval - The FDA approved Yuviwel, a prodrug aimed at increasing linear growth in children aged two years and older with achondroplasia, based on data from three randomized clinical trials [2] - Achondroplasia is a rare genetic disorder characterized by dwarfism, with short limbs, a normal-sized torso, and a large head [2] - Ascendis Pharma plans to make Yuviwel available through prescribing physicians in the U.S. in early Q2 2026 [2] Clinical Trial Results - Pivotal week 52 results from the ApproaCH Trial of TransCon CNP (navepegritide) in children with achondroplasia were published in JAMA Pediatrics [3] - Treatment with TransCon CNP resulted in significantly higher annualized growth velocity (AGV) at week 52 compared to placebo, along with improved lower-limb alignment, body proportionality, and positive changes in health-related quality of life [4] Strategic Developments - The approval includes a Rare Pediatric Disease Priority Review Voucher, which may expedite future drug applications [5] - This development represents a significant advancement in treatment options for achondroplasia, providing a new growth avenue for Ascendis Pharma's portfolio [5] Stock Performance - The stock is currently trading 0.42% below its 20-day simple moving average (SMA) and 2.45% above its 100-day SMA, indicating short-term weakness but longer-term strength [6] - Over the past 12 months, shares have significantly increased and are closer to their 52-week highs than lows [6] Technical Analysis - The RSI is at 50.00, indicating neutral territory, suggesting the stock is neither overbought nor oversold [7] - The MACD is at 0.15, below its signal line at 0.22, indicating bearish pressure on the stock [7] - The combination of neutral RSI and bearish MACD suggests mixed momentum [7]

Core Viewpoint - BioMarin Pharmaceutical has agreed to acquire Amicus Therapeutics for $4.8 billion, enhancing its portfolio with therapies for lysosomal storage disorders [1] Group 1: Acquisition Details - BioMarin will pay $14.50 per share for Amicus, representing a 33% premium over Amicus' stock value of $10.89 on December 18 [1] - This acquisition is the largest in BioMarin's history and has resulted in a 17.71% increase in BioMarin's stock price, from $51.95 to $61.15 [2] Group 2: Acquired Therapies - The acquisition includes rights to Amicus' Fabry disease therapy, Galafold, which generated $458.1 million in 2024, an 18% increase from 2023 [2] - Galafold is the only FDA-approved chaperone therapy for Fabry disease and has market exclusivity until January 30, 2027, following a patent litigation with Teva Pharmaceuticals [3] - BioMarin will also acquire the FDA-approved Pompe disease combination therapy, Pombiliti plus Opfolda, which generated $22 million in 2024 [4][5] Group 3: Future Growth Strategy - BioMarin has been focusing on growth in the pharmaceutical sector, undergoing significant restructuring in 2024, which included laying off 225 employees [7] - The company has adopted a strong dealmaking strategy, signing 10 deals in 2025, the highest number since 2010 according to GlobalData's Pharmaceutical Intelligence Center [7] - BioMarin is also acquiring rights to the investigational oral small molecule DMX-200, currently in Phase III trials for focal segmental glomerulosclerosis [6]